Author

Arooj Akhtar

Observed names: A Akhtar, Akhtar, Arooj

Observed institutions: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Howard Hughes Medical Institute, Harvard University, Johns Hopkins University, Duke University, University of Alabama, University of California, San Francisco, Cornell University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, National Eye Institute, Sidney Kimmel Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, Weill Cornell Medicine, UNC Lineberger Comprehensive Cancer Center, Georgetown Lombardi Comprehensive Cancer Center

OpenAlex ID: A5113614590

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2013 · Ayca Gucalp, Sara Tolaney, et al. · Clinical Cancer Research · 750

Abstract P6-05-02: Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(−) metastatic breast cancer (MBC) (TBCRC011)

2012 · A Gucalp, S Tolaney, et al. · Cancer Research · 4

Supplementary Figure 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Supplementary Figure 2 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Supplementary Legend from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Supplementary Table 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Supplementary Legend from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Supplementary Table 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Supplementary Figure 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Supplementary Figure 2 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Data from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Data from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

2023 · Ayca Gucalp, Sara Tolaney, et al.

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

2020 · Gonzalez, Joseph M., Carey, Lisa A., et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)

Evaluation of Possible Candidate Genes Involved in Optic Fissure Closure

2008 · Arooj Akhtar, Jacob D. Brown, et al. · Investigative Ophthalmology & Visual Science

Two Putative Zinc-Finger Containing Proteins Are Necessary for Proper Optic Fissure Closure in a Zebrafish Model

2008 · Jacob D. Brown, Sunit Dutta, et al. · Investigative Ophthalmology & Visual Science

Works count: 15

Citation count: 754

H-index: 2

I10-index: 1